FKONCO

Dabur Pharma Limited has informed the Exchange regarding outcome of recently concluded second Board of Directors Meeting of the Company held on August 11, 2008. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/DaburPharma_OutcomeofBM_11082008_01.zip target=NEW> For more details click here.</a>

Dabur Pharma Limited has informed the Exchange regarding outcome of recently concluded Board of Directors Meeting of the Company held on August 11, 2008. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/DaburPharma_OutcomeofBM_11082008.zip target=NEW> For more details click here.</a>

Dabur Pharma Limited has informed the Exchange that: "Mr. Ajay Kumar Vij has resigned from the Board as Director of the Company w.e.f. the close of business hours on Friday, 8th August 2008. Further to inform that Mr. Ajay Kumar Vij will continue as Chief Executive Officer of the Company".

Dabur Pharma Limited has informed the Exchange regarding cancellation/ option to surrender the Stock Options. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Dabur_UPDATE_05082008.zip target=NEW> For more details click here.</a>

Dabur Pharma Limited has informed regarding a press release dated July 31, 2008, titled "Dabur Pharma Declares Financial Results: Registers 11.7% Growth". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Daburpharma_PR_31072008.zip target=NEW> For more details click here.</a>

Life Insurance Corporation of India has informed the Exchange that "Life Insurance Corporation of India has sold 2623993 equity shares face value of Rs.1/- each of Dabur Pharma Ltd. @ Rs.76.50 per share".

Dabur Pharma Limited has informed the Exchange regarding the outcome of Annual General Meeting held on July 21, 2008. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/DabarPharma_OutAGM_22072008.zip target=NEW> For more details click here.</a>

Dabur Pharma Limited has informed the Exchange that : "The Company has obtained requisite Shareholders approval through Postal Ballot pursuant to Section 192A of the Companies Act, 1956 on the Special resolution for cancellation of 1481226 employees Stock Options granted to five eligible employees and option to other employees to surrender their outstanding options/shadow options".

Dabur Pharma Limited has informed the Exchange that the Board of Directors of the Company at its meeting held on May 30, 2008 have: 1) Decided to convene the Annual General Meeting of the Company on July 21, 2008. 2) Fixed the Book Closure period for the annual closure from July 07, 2008 to July 21, 2008 (both days inclusive). 3) Not recommended any dividend for the year. 4) Recommended the appointment of Mr. Mohit Burman, who was appointed as an additional director on the board of the Company on July 26, 2007, as a director liable to retire by rotation. 5) Recommended the re-appointment of Mr

Dabur Pharma Limited has informed the Exchange regarding a press release dated May 30, 2008, titled "Dabur Pharma announces results for fiscal 2007-08". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/daburpharma_pr_30052008.zip target=NEW> For more details click here.</a>

Dabur Pharma Limited has informed the Exchange regarding a press release dated May 21, 2008, titled "Dabur Pharma receives USFDA approval for Generic Mitoxantrone". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Dabur_PR_21052008.zip target=NEW> For more details click here.</a>

Dabur Pharma Limited has informed the Exchange that pursuant to the provision of Section 192A of the Companies Act, 1956, read with the Companies (Passing of the Resolution by Postal Ballot) Rules, 2001, the Company is seeking the consent of its members through Special Resolution proposed to be passed by Postal Ballot in respect of the following Special Business: 1) Special resolution for cancellation of 1481226 outstanding Employee Stock Options and providing an option to the other employees to surrender their outstanding options/ shadow options. The Company has appointed Ms. Kiran Sharma, Pr

Morgan Stanley India Company Private Limited has informed the Exchange regarding a Public Announcement ("PA") being issued by them ("Manager to the Offer"), on behalf of Fresenius Kabi (Singapore) Pte Ltd ("FKSL" / the "Acquirer") and Fresenius Kabi Austria GmbH ("FKA"), Fresenius SE ("FSE") and Fresenius Finance B.V. ("FEB") being the Persons Acting in Concert ("PAC") with the Acquirer, in compliance with Regulations 10 and 12 of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 1997 and subsequent amendments thereto (the "SEBI (SAST) Re

Dabur Pharma Limited has informed the Exchange that: "The new unit of the Company situated at Kishanpura, Distt. Solan, Himachal Pradesh has commenced its commercial production."

Dabur Pharma Limited has informed the Exchange that by an order on March 11, 2008 as amended on March 27, 2008 read with order dated October 17, 2003, the Hon'ble High Court of Delhi has directed that a meeting of the equity shareholders and a meeting of the unsecured creditors (as on December 31, 2007) of Dabur Pharma Limited be held on May 18, 2008 for the purpose of considering and, if thought fit, approving, with or without modification(s), the proposed modification of the Scheme of Arrangement sanctioned by the Hon'ble High Court on October 17, 2003 to the extent that property bearing Plo

Dabur Pharma Limited has informed the Exchange that: "The Share Allotment Committee of the Board of Directors of the Company at their meeting held on 23.04.2008, i.e. today, has allotted 7600 equity Shares of the Company pursuant to exercise of vested Employees Stock Option by 5 employees applicants under "ESOP 2004. These shares have been allotted pursuant to In-principle approval already received from the Stock Exchanges."

Dabur Pharma Limited has informed the Exchange regarding a press release dated April 21, 2008, titled "Burmans' of the Dabur Group unlock significant value from Dabur Pharma". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Daburpharma_PR_21042008.zip target=NEW> For more details click here.</a>

Dabur Pharma Limited has informed the Exchange vide its letter dated April 18, 2008 that "at the meeting of the Board of Directors of Dabur Pharma Limited ("Company") held today, the Board has, subject to the approval of the shareholders and other necessary statutory and regulatory approvals, approved the following: 1) the cancellation of 1,481,226 outstanding employee stock options granted to certain employees of the Company. 2) Providing an option to the other employees of the Company to surrender their outstanding stock options/ shadow options, in consideration of cash compensation of Rs. 9

Dabur Pharma Limited has informed the Exchange that: "The promoters and certain other shareholders of Dabur Pharma Limited ("Company'') have executed share purchase agreements with Fresenius Kabi (Singapore) Pte Ltd ("Fresenius") pursuant to which Fresenius will acquire approximately 73.27% of the total issued and paid-up equity share capital of the Company at Rs.76.50 per equity share, subject to fulfillment of certain conditions precedent including receipt of necessary regulatory approvals and the compliance by Fresenius with public offer requirements under the SEBI (Substantial Acquisition

Dabur Pharma Limited has informed the Exchange regarding a press release dated April 09, 2008, titled "Dabur Pharma Signs Agreement with Government Pharmaceutical Organization, Thailand for Cost effective Anticancer Product". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/DaburPharma_PR_09042008.zip target=NEW> For more details click here.</a>

Dabur Pharma Limited has informed the Exchange that: "The Company shall be publishing audited results for the financial year ended 31.03.2008 within three months from the end of financial year i.e. 31st March, 2008, the un-audited results will not be adopted / published separately".

Dabur Pharma Limited has informed the Exchange regarding a press release dated March 11, 2008, titled "Irinotecan Gets Approval in Italy & Denmark". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/DaburPharma_PR_11032008.zip target=NEW> For more details click here.</a>

Dabur Pharma Limited has informed the Exchange regarding a press release dated February 28, 2008, titled "Dabur Pharma Announces Approval & Launch of Irinotecan Hydrochloride Injection in United States". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). <a href=/content/corporate/DaburPharma_PR_29022008.zip target=NEW> For more details click here.</a>

Dabur Pharma Limited has informed the Exchange regarding a press release dated January 30, 2008, titled "Dabur Pharma's Nanoxel Receives DCGI Approval for Additional Indications". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/daburph_PR_31012008.zip target=NEW> For more details click here.</a>

Dabur Pharma Limited has informed the Exchange regarding a press release dated January 30, 2008, with respect to Unaudited Financial results for the third Quarter ended December 31, 2007. A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Daburpharma_PR_30012008.zip target=NEW> For more details click here.</a>

Dabur Pharma Limited has informed the Exchange that with a view to provide better and efficient services to investors, the management has decided to change the existing Registrar and Share transfer agent i.e. M/s. MCS Limited, Sri Venkatesh Bhavan, W-40 Okhla Industrial Area, Phase II, New Delhi - 110020 to M/s. Karvy Computershare Private Limited, Plot no.17-24, Vithalrao Nagar, Madhapur, Hyderabad - 500086 w.e.f. January 12, 2008. The Company has made a request to MCS Limited, New Delhi for their NOC.

Dabur Pharma Limited has informed the Exchange regarding a press release dated October 30, 2007, titled "Dabur Pharma Receives USFDA Approval For Generic Irinotecan". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements)<a href=/content/corporate/Daburpharma_PR_30102007.zip target=NEW> For more details click here.</a>

Dabur Pharma Limited has informed the Exchange regarding a press release with respect to its unaudited financial results for the quarter ended September 30, 2007. A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements)<a href=/content/corporate/Daburpharma_PR_26102007.zip target=NEW> For more details click here.</a>

Dabur Pharma Limited has informed the Exchange regarding a release dated October 24, 2007, titled "Dabur Pharma signs Agreement for Spanish Market". A copy of the release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Dabur_PR_24102007.zip target=NEW> For more details click here.</a>

Dabur Pharma Limited has informed the Exchange that the Compensation Committee of Directors, constituted for the purpose of grant of ESOP to the eligible employees and Directors of the Company, has granted 19,88,700 Options under ESOP 2004 scheme at their meeting held on October 10, 2007. The Company has further informed the Exchange that out of 19,88,700 options, 9,08,500 Options will be vested over a period of 4 years @25% each year on October 10th every year (Plan I) and remaining 10,80,200 options will be vested in 4 years (Plan II) as detailed below - i) October 10, 2008 - 15%; ii) Octobe

Dabur Pharma Limited has informed the Exchange that Mr. C K Birla has, vide letter dated August 29, 2007, submitted his resignation from the Board as an Independent Director w.e.f. August 29, 2007.

Dabur Pharma Limited has submitted to the Exchange a copy of the Minutes of the Annual General Meeting of the Company held on July 25, 2007. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/DABUR_AGM_270807.zip target=NEW> For more details click here.</a>

Dabur Pharma Limited has informed the Exchange that: "Dabur Pharma Limited, India's leading oncology player, has received final approval from the US Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Epirubicin injection 50mg and 200mg.

Dabur Pharma Limited has informed the Exchange that the Annual General Meeting of the Company has been convened on July 25, 2007 wherein following resolutions have been passed: 1) Dr. Anand C Burman, Mr. P D Narang and Dr. Naresh Trehan, Directors of the Company have been re-appointed as directors liable to retire by rotation. 2) Mr. Ashok Vij has been appointed as Director of the Company. 3) M/s. G Basu & Co. Chartered Accountants, has been re-appointed as auditors to hold office from the conclusion of this Annual General Meeting until the conclusion of the next Annual General Meeting. 4) M/s

Dabur Pharma Limited has informed the Exchange that the Board of Directors of the Company at its meeting held on July 26, 2007 has inter alia, taken the following decisions: (1) Dr Anand C Burman has stepped down from the Non-Executive Chairmanship and has been appointed as Managing Director of the Company. (2) Mr. Mohit Burman has been appointed as Additional Director and Non-Executive Chairman of the Company. (3) Approved appointment of Mr. Nikhil Kulshreshtha, Company Secretary and Head - Legal as its new Compliance Officer.

Dabur Pharma Limited has informed the Exchange regarding a press release dated July 26, 2007, titled "Dabur Pharma Reports Excellent Financial Results for First Quarter FY'08." A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/dabur_PR_260707.zip target=NEW> For more details click here.</a>

Dabur Pharma Limited has informed the Exchange that: "Mr. Nikhil Kulshreshtha has been appointed as "Company Secretary and Head-Legal" of Dabur Pharma Limited w.e.f July 21, 2007".

Dabur Pharma Limited has submitted to the Exchange a copy of the Notice of Annual General Meeting of the members of the Company scheduled to be held on July 25, 2007. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/DaburPharma_AGMNotice.zip target=NEW> For more details click here.</a>

Dabur Pharma Limited has informed the Exchange that Mr. Shailendra Tandon has joined the Company as Chief Financial Officer w.e.f. June 26, 2007. Mr. Shailendra Tandon will sign all the documents, papers & filing etc. as per stock Exchange requirements till Company Secretary/Compliance officer is appointed.

Dabur Pharma Limited has informed the Exchange that "Dabur Pharma Limited, and Dabur Oncology Plc., UK submitted two Abbreviated New Drug Applications (ANDAs), with Para-IV Certifications with the U.S. Food and Drug Administration (US FDA) seeking Marketing Approval for Generic Versions of Eloxatin(R), which contains the Active Ingredient, Oxaliplatin. Eloxatin(R) which is marketed by Sanofi-Aventis, as an injectable, is used in treatement of bowel cancer and generated sales of approximately 1.7 billion Euros (US $ 2.3 billion). Generic versions of Eloxatin (Oxaliplatin) are available in sever

Dabur Pharma Limited has informed the Exchange that: "Mr. Gauri Shankar Mishra has resigned as Company Secretary of the Company w.e.f. 19th June, 2007. The Company is in the process of appointing a new Company Secretary in his place".

Dabur Pharma Limited has informed the Exchange that "Mr. Vardhan Dharkar has resigned as Chief Financial Officer of the Company w.e.f. 1st June, 2007 and accordingly also relinquished his position as the Compliance Officer, effective the above said date. The Company is in the process of appointing a new Compliance Officer in his place".

Dabur Pharma Limited has informed the Exchange that: "Mr. G S Mishra has been appointed as a Company Secretary of Dabur Pharma Limited".

Dabur Pharma Limited has informed the Exchange that the Board of Directors at their meeting held on May 17, 2007 have: 1) Decided to convene the Annual General Meeting on July 25, 2007. 2) Fixed the Book Closure period for annual closure from July 16, 2007 to July 25, 2007, both days inclusive. 3) The Directors have not recommended any dividend for the year. 4) Mr. Ajay Vij has been appointed as the Chief Executive Officer of the Company.

Dabur Pharma Limited has informed the Exchange that: "The Company has provided exclusive E-mail IDs to enable investors to register their Complaints. The investors can register their complaints with the Secretarial Deptt. of the Company at pharmainvestors@dabur.com and also with Investor Service/Grievance Redressal Officer Mr. Rajat Agarwal at mail ID rajat.aggarwal@daburpharma.com".

Dabur Pharma Limited has informed the Exchange that: "Dabur Oncology Plc, the Wholly Owned Subsidiary of Dabur Pharma in UK, has incorporated a Subsidiary Company in the U.S.A., which will now be directly responsible for Sales, Marketing and Distribution of Oncology Products in U.S.A.".

Dabur Pharma Limited has informed the Exchange that "The sales and distribution agreement entered into between Dabur Oncology Plc, a wholly Owned Subsidiary Company of Dabur Pharma Ltd. and Hospira Inc. for exclusive supply of oncology products for sales and distribution in the USA by Hospira Inc., has been terminated with mutual consent. Going forward the Company will sell and distribute its entire range of oncology products in USA through its own infrastructure.

Dabur Pharma Limited has informed the Exchange that "Since the Company shall be publishing audited results for the year ended 31.03.2007 within three months from the end of financial year i.e. 31st March, 2007, the un-audited results will not be adopted /published separately".

Dabur Pharma Limited has informed the Exchange that "The entire transaction relating to sale of non oncology formulations division to Alembic Limited have been completed and non oncology formulations division is transferred to Alembic Limited".

Dabur Pharma Limited has informed the Exchange that the Share Allotment Committee of the Board of Directors of the Company at their meeting held on 29.03.2007, has allotted 291086 equity Shares of the company pursuant to exercise of vested Employees Stock Option by 68 employees applicants under "ESOP 2004".